See how top analysts and institutions rate MSFT — including buy, hold, and sell recommendations.
| Rating Source | Action | Rating | Target Price | Updated |
|---|---|---|---|---|
| Citigroup | Reiterated | Buy | $680 → $682 | 2025-10-22 |
| Mizuho | Reiterated | Outperform | $625 → $640 | 2025-10-17 |
| Wells Fargo | Reiterated | Overweight | $650 → $675 | 2025-10-06 |
| BofA Securities | Reiterated | Buy | $585 → $640 | 2025-07-31 |
| Jefferies | Reiterated | Buy | $600 → $675 | 2025-07-31 |
| Mizuho | Reiterated | Outperform | $540 → $625 | 2025-07-31 |
| Wedbush | Reiterated | Outperform | $600 → $625 | 2025-07-31 |
| KeyBanc Capital Markets | Upgrade | Sector Weight → Overweight | $630 | 2025-07-31 |
| TD Cowen | Reiterated | Buy | $580 → $640 | 2025-07-31 |
| UBS | Reiterated | Buy | $600 → $650 | 2025-07-31 |
| Morgan Stanley | Reiterated | Overweight | $530 → $582 | 2025-07-31 |
| BMO Capital Markets | Reiterated | Outperform | $550 → $650 | 2025-07-31 |
| Barclays | Reiterated | Overweight | $550 → $625 | 2025-07-31 |
| Bernstein | Reiterated | Outperform | $540 → $637 | 2025-07-31 |
| Wells Fargo | Reiterated | Overweight | $600 → $650 | 2025-07-31 |
| Oppenheimer | Reiterated | Outperform | $600 → $630 | 2025-07-31 |
| Citigroup | Reiterated | Buy | $605 → $613 | 2025-07-22 |
| Mizuho | Reiterated | Outperform | $500 → $540 | 2025-07-16 |
| Cantor Fitzgerald | Reiterated | Overweight | $512 → $581 | 2025-07-16 |
| Oppenheimer | Upgrade | Perform → Outperform | $600 | 2025-07-09 |
| DA Davidson | Reiterated | Buy | $500 → $600 | 2025-07-02 |
| Wedbush | Reiterated | Outperform | $515 → $600 | 2025-06-25 |
| Citigroup | Reiterated | Buy | $540 → $605 | 2025-06-11 |
| Date | Strong Buy | Buy | Hold | Sell | Strong Sell |
|---|---|---|---|---|---|
| November 2025 | 12 | 45 | 0 | 0 | 0 |
| October 2025 | 12 | 45 | 0 | 0 | 0 |
| September 2025 | 13 | 44 | 1 | 0 | 0 |
| August 2025 | 12 | 43 | 1 | 0 | 0 |
The majority of institutional investors have issued a "Buy" rating for MSFT, and analyst sentiment aligns closely, with very few "Sell" recommendations. This suggests a broadly favorable outlook for the stock's performance.
